Volume 28, Issue 6 (1-2026)
J Arak Uni Med Sci 2026, 28(6): 459-465 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Khodadadi R, Bayat S, Sadati S, Gholami M. Identification of a Novel Nonsense Variant in ABCD1 Gene in a Patient with Adrenoleukodystrophy by Whole Exome Sequencing. J Arak Uni Med Sci 2026; 28 (6) :459-465
URL: http://jams.arakmu.ac.ir/article-1-8073-en.html
URL: http://jams.arakmu.ac.ir/article-1-8073-en.html
1- Department of Biology, Faculty of Science, Arak University, Arak, Iran
2- Department of Biochemistry and Genetics, School of Medicine, Arak University of Medical Sciences, Arak, Iran
3- Department of Genetics, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran
4- Department of Biochemistry and Genetics, School of Medicine, Arak University of Medical Sciences, Arak, Iran ,mtu.q220@gmail.com
2- Department of Biochemistry and Genetics, School of Medicine, Arak University of Medical Sciences, Arak, Iran
3- Department of Genetics, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran
4- Department of Biochemistry and Genetics, School of Medicine, Arak University of Medical Sciences, Arak, Iran ,
Abstract: (532 Views)
Introduction: Adrenoleukodystrophy, inherited in an X-linked manner, is a progressive neurodegenerative disorder. It is the most common peroxisomal disorder and results from mutations in the ABCD1 gene. The disease manifests with a wide range of symptoms that can vary depending on the age of onset. Its estimated prevalence is approximately 1 in 17,000 live births. This study aimed to analyze the genetic profile of an individual with X-linked Adrenoleukodystrophy (X-ALD) through whole-exome sequencing.
Methods: A peripheral blood sample was obtained from a patient with clinical features consistent with adrenoleukodystrophy. Following the extraction of genomic DNA, whole-exome sequencing (WES) was conducted to identify potential genetic variants. Subsequent data analysis revealed a disease-causing mutation, which was confirmed by Sanger sequencing. The patient's mother was also tested to determine her carrier status. All ethical considerations were observed in accordance with the guidelines established by the National Committee for Ethics in Biomedical Research and the COPE standards.
Results: The study identified a hemizygous variant in the ABCD1 gene, (NM_000033.4) c.1777G>T (p.Gly593Ter), likely pathogenic, confirming the patient's diagnosis of X-linked Adrenoleukodystrophy (X-ALD). Genetic analysis of the patient’s mother revealed that she was a carrier.
Conclusions: A hemizygous variant in the ABCD1 gene was identified using whole exome sequencing. This variant can lead to X-linked Adrenoleukodystrophy.
Methods: A peripheral blood sample was obtained from a patient with clinical features consistent with adrenoleukodystrophy. Following the extraction of genomic DNA, whole-exome sequencing (WES) was conducted to identify potential genetic variants. Subsequent data analysis revealed a disease-causing mutation, which was confirmed by Sanger sequencing. The patient's mother was also tested to determine her carrier status. All ethical considerations were observed in accordance with the guidelines established by the National Committee for Ethics in Biomedical Research and the COPE standards.
Results: The study identified a hemizygous variant in the ABCD1 gene, (NM_000033.4) c.1777G>T (p.Gly593Ter), likely pathogenic, confirming the patient's diagnosis of X-linked Adrenoleukodystrophy (X-ALD). Genetic analysis of the patient’s mother revealed that she was a carrier.
Conclusions: A hemizygous variant in the ABCD1 gene was identified using whole exome sequencing. This variant can lead to X-linked Adrenoleukodystrophy.
Type of Study: Original Atricle |
Subject:
Basic Sciences
Received: 2025/08/4 | Accepted: 2025/09/21
Received: 2025/08/4 | Accepted: 2025/09/21
References
1. Parikh S, Bernard G, Leventer RJ, van der Knaap MS, van Hove J, Pizzino A, et al. A clinical approach to the diagnosis of patients with leukodystrophies and genetic leukoencephelopathies. Mol Genet Metab. 2015;114(4):501-15. pmid: 25655951 doi: 10.1016/j.ymgme.2014.12.434.
2. National Institute of Neurological Disorders and Stroke. Leukodystrophy. National Institutes of Health. Available from: https://www.ninds.nih.gov/health-information/disorders/leukodystrophy
3. Bradbury AM, Bongarzone ER, Sands MS. Krabbe disease: New hope for an old disease. Neurosci Lett. 2021:752:135841. pmid: 33766733 doi: 10.1016/j.neulet.2021.135841.
4. Messina M, Gissen P. Atidarsagene autotemcel for metachromatic leukodystrophy. Drugs Today (Barc). 1998;59(2):63–70. pmid: 36811406 doi: 10.1358/dot.2023.59.2.3461911.
5. Wei H, Moffett JR, Amanat M, Fatemi A, Tsukamoto T, Namboodiri AM, et al. S. (2022). The pathogenesis of, and pharmacological treatment for, Canavan disease. Drug Discov Today. 2022;27(9):2467-83. pmid: 35636725 doi: 10.1016/j.drudis.2022.05.019
6. Pajares MA, Hernández-Gerez E, Pekny M, Pérez-Sala D. Alexander disease: the road ahead. Neural Regen Res. 2023;18(10):2156-60. pmid: 37056123 doi: 10.4103/1673-5374.369097
7. Singh R, Samanta D. Pelizaeus-Merzbacher Disease. In StatPearls. StatPearls Publishing; 2023.
8. Volmrich AM, Cuénant LM, Forghani I, Hsieh SL, Shapiro LT. ABCD1 gene mutations: mechanisms and management of adrenomyeloneuropathy. Appl Clin Genet. 2022; 15:111-23. pmid: 35983253 doi: 10.2147/TACG.S359479
9. Cappa M, Todisco T, Bizzarri C. X-linked adrenoleukodystrophy and primary adrenal insufficiency. Front Endocrinol (Lausanne). 2023:14:1309053. pmid: 38034003 doi: 10.3389/fendo.2023.1309053
10. Jia Y, Zhang Y, Lei J, Wang W, Lei J, Yang Z, et al. Structure insights of the human peroxisomal ABC transporter ALDP. Elife. 2022:11:e75039. pmid: 36374178 doi: 10.7554/eLife.75039
11. Sevin C, Hatteb S, Clément A, Bignami F, Chillotti L, Bugnard F, et al. Childhood cerebral adrenoleukodystrophy (CCALD) in France: epidemiology, natural history, and burden of disease - A population-based study. Orphanet J Rare Dis. 2023;18(1):238. pmid: 37563635 doi: 10.1186/s13023-023-02843-x
12. Olgac A, Kasapkara ÇS, Derinkuyu B, Yüksel D, Çetinkaya S, Aksoy A, et al. Retrospective evaluation of patients with X-linked adrenoleukodystrophy with a wide range of clinical presentations: a single center experience. J Pediatr Endocrinol Metab. 2021;34(9):1169-79. pmid: 34162029 doi: 10.1515/jpem-2021-0032
13. Moser AB, Kreiter N, Bezman L, Lu S, Raymond GV, Naidu S, et al. Plasma very long chain fatty acids in 3,000 peroxisome disease patients and 29,000 controls. Ann Neurol. 1999;45(1):100-10. pmid: 9894883 doi: 10.1002/1531-8249(199901)45:1<100::aid-art16>3.0.co;2-u.
14. Polgreen LE, Chahla S, Miller W, Rothman S, Tolar J, Kivisto T, et al. Early diagnosis of cerebral X-linked adrenoleukodystrophy in boys with Addison’s disease improves survival and neurological outcomes. Eur J Pediatr. 170(8):1049-54. pmid: 21279382 doi: 10.1007/s00431-011-1401-1.
15. Berger J, Forss-Petter S, Eichler FS. Pathophysiology of X-linked adrenoleukodystrophy. Biochimie. 2014;98(100):135–42. pmid: 24316281 doi: 10.1016/j.biochi.2013.11.023
16. Wiesinger C, Eichler FS, Berger J. The genetic landscape of X-linked adrenoleukodystrophy: inheritance, mutations, modifier genes, and diagnosis. Appl Clin Genet. 2015;8:109–21. pmid: 25999754 doi: 10.2147/TACG.S49590
17. Fourcade S, López-Erauskin J, Galino J, Duval C, Naudi A, Jove M, et al. Early oxidative damage underlying neurodegeneration in X-adrenoleukodystrophy. Hum Mol Genet. 2008;17(12):1762-73. pmid: 18344354 doi: 10.1093/hmg/ddn085
18. Ofman R, Dijkstra IM, van Roermund CW, Burger N, Turkenburg M, van Cruchten A, et al. The role of ELOVL1 in very long-chain fatty acid homeostasis and X-linked adrenoleukodystrophy. EMBO Mol Med. 2010;2(3):90-7. pmid: 20166112 doi: 10.1002/emmm.201000061
19. Mehrpour M, Gohari F, Dizaji MZ, Ahani A, Malicdan MCV, Behnam B. An ABCD1 Mutation (c.253dupC) Caused Diverse Phenotypes of Adrenoleukodystrophy in an Iranian Consanguineous Pedigree. J Mol Genet Med. 2016;10(2):222. pmid: 27489563 doi: 10.4172/1747-0862.1000222
20. Emamalizadeh B, Daneshmandpour Y, Tafakhori A, Ranji-Burachaloo S, Shafiee S, Ghods E, et al. Novel ABCD1 gene mutations in Iranian pedigrees with X-linked adrenoleukodystrophy. J Pediatr Endocrinol Metab. 2019;32(11):1207-15. pmid: 31665121 doi: 10.1515/jpem-2019-0244.
21. Dong SW, Xiao LM, Sun YH, Li GH, Xie YX, Wang MW, et al. Novel ABCD1 Variants in X-Linked Adrenoleukodystrophy. Clin Genet. 2025;108(4):450-6. pmid: 40210590 doi: 10.1111/cge.14752.
22. Engelen M, Kemp S, De Visser M, van Geel BM, Wanders RJ, Aubourg P. X-linked adrenoleukodystrophy (X-ALD): clinical presentation and guidelines for diagnosis, follow-up and management. Orphanet J Rare Dis. 2012;7:51. pmid: 22889154 doi: 10.1186/1750-1172-7-51
23. Yan F, Wang W, Ying H, Li H, Chen J, Xu C. S149R, a novel mutation in theABCD1gene causing X-linked adrenoleukodystrophy. Oncotarget. 2017;8(50):87529–38. pmid: 29152099 doi: 10.18632/oncotarget.20974
24. Dohr KA, Tokic S, Gastager-Ehgartner M, Stojakovic T, Dumic M, Plecko B, et al. Two Single Nucleotide Deletions in the ABCD1 Gene Causing Distinct Phenotypes of X-Linked Adrenoleukodystrophy. Int J Mol Sci. 2023;24(6):5957. pmid: 36983033 doi: 10.3390/ijms24065957
25. Cartier N, Hacein-Bey-Abina S, Bartholomae CC, Veres G, Schmidt M, Kutschera I, Vidaud M, et al. Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy. Science. 2009;326(5954):818-23. pmid: 19892975 doi: 10.1126/science.1171242
26. Gong Y, Mu D, Prabhakar S, Moser A, Musolino P, Ren J, et al. Adenoassociated virus Serotype 9-Mediated gene therapy for X-Linked adrenoleukodystrophy. Mol Ther. 2015;23(5):824-34. pmid: 25592337 doi: 10.1038/mt.2015.6
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
